Side-by-side research comparison of Liraglutide and Retatrutide across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. 1 head-to-head study plus 479 on Liraglutide and 153 on Retatrutide.
| Liraglutide | Retatrutide | |
|---|---|---|
| Drug class | glp 1 agonist | glp 1 agonist, gip agonist, glucagon agonist |
| Studies in corpus | 479 | 153 |
| Highest evidence tier | meta analysis | meta analysis |
| Evidence tier mix | rct · 6 cohort · 2 review · 1 meta analysis · 1 in vitro · 2 | review · 49 preclinical animal · 11 meta analysis · 25 other · 21 rct · 23 in vitro · 1 |
| Studies with explicit sample size | 3 | 2 |
| Head-to-head studies in corpus | 1 | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Liraglutide and Retatrutide batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 6 Liraglutide batches across 4 manufacturers, 99.6% avg purity.
We tested 15763 Retatrutide batches across 2530 manufacturers, 99.67% avg purity.
We hold deeper lab coverage on Retatrutide (15763 batches tested). Retatrutide edges ahead on average measured purity (99.6% vs 99.67%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Studies in our corpus that mention both Liraglutide and Retatrutide — the gold-standard direct comparison evidence.
This review underscores a paradigm shift in metabolic disease management, moving beyond single-target approaches to powerful multi-agonist strategies. For individuals managing T2DM, obesity, or MASLD, the emergence of dual and triple incretin agonists offer…
Looking for vendor-level purity, endotoxin, and HPLC data on Liraglutide or Retatrutide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.